0.9% Saline for IV administration
Sponsors
Avidity Biosciences Inc.
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)Myotonic Dystrophy Type 1
Phase 3
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Active, not recruitingCTIS2024-511378-60-00
Start: 2024-12-11Target: 39Updated: 2025-11-18
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Not yet recruitingCTIS2025-521012-18-00
Target: 80Updated: 2025-11-07